IQVIA Holdings Inc. $IQV Shares Bought by Osaic Holdings Inc.

Osaic Holdings Inc. boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 32.0% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 71,103 shares of the medical research company’s stock after purchasing an additional 17,217 shares during the period. Osaic Holdings Inc.’s holdings in IQVIA were worth $11,233,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Orion Porfolio Solutions LLC boosted its stake in shares of IQVIA by 7.0% in the second quarter. Orion Porfolio Solutions LLC now owns 19,552 shares of the medical research company’s stock worth $3,081,000 after buying an additional 1,282 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in IQVIA in the second quarter valued at approximately $242,000. Cape Investment Advisory Inc. boosted its position in IQVIA by 34.0% in the 2nd quarter. Cape Investment Advisory Inc. now owns 10,710 shares of the medical research company’s stock worth $1,688,000 after purchasing an additional 2,719 shares in the last quarter. Advisory Services Network LLC grew its stake in shares of IQVIA by 49.3% during the 2nd quarter. Advisory Services Network LLC now owns 5,836 shares of the medical research company’s stock worth $920,000 after purchasing an additional 1,927 shares during the period. Finally, State of Wyoming increased its holdings in shares of IQVIA by 369.0% during the 2nd quarter. State of Wyoming now owns 3,940 shares of the medical research company’s stock valued at $621,000 after purchasing an additional 3,100 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 0.8%

Shares of IQV opened at $220.75 on Friday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $234.29. The stock has a market cap of $37.59 billion, a PE ratio of 30.28, a price-to-earnings-growth ratio of 2.50 and a beta of 1.37. The firm’s fifty day moving average is $219.06 and its two-hundred day moving average is $192.18. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the firm posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on IQV shares. Citigroup raised their price target on shares of IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research report on Wednesday, October 29th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. Redburn Partners set a $214.00 price objective on IQVIA in a research report on Wednesday, September 3rd. Morgan Stanley boosted their price target on shares of IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Finally, HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $243.19.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.